Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

M1000000

Methotrexate

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

(+)-Amethopterin, 4-Amino-10-methylfolic acid, 4-Amino-N10-methylpteroyl-L-glutamic acid, Antifolan, MTX, Methylaminopterin

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C20H22N8O5
Número CAS:
59-05-2
Peso molecular:
454.44
Beilstein:
70669
Número MDL:
MFCD00064370
Código UNSPSC:
41116107
ID de substância PubChem:
329817845
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

methotrexate

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

Formato

neat

cadeia de caracteres SMILES

CN(Cc1cnc2nc(N)nc(N)c2n1)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O

InChI

1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1

chave InChI

FBOZXECLQNJBKD-ZDUSSCGKSA-N

Informações sobre genes

human ... DHFR(1719)

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Methotrexate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

M1000008

Methotrexate impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000602

Methotrexate for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0000663

Methotrexate impurity C, European Pharmacopoeia (EP) Reference Standard

Y0000664

Methotrexate impurity E, European Pharmacopoeia (EP) Reference Standard

Y0001668

Methotrexate for system suitability, European Pharmacopoeia (EP) Reference Standard

1414003

Methotrexate, United States Pharmacopeia (USP) Reference Standard

1413988

R-Methotrexate, United States Pharmacopeia (USP) Reference Standard

1413999

Methotrexate System Suitability Mixture, United States Pharmacopeia (USP) Reference Standard

1414025

Methotrexate Related Compound B, United States Pharmacopeia (USP) Reference Standard

1414036

Methotrexate Related Compound C, United States Pharmacopeia (USP) Reference Standard

1414058

Methotrexate Related Compound E, United States Pharmacopeia (USP) Reference Standard

Pictogramas

Skull and crossbonesHealth hazard
GHS06,GHS08

Palavra indicadora

Danger

Frases de perigo

H301,H341,H360D,H372

Classificações de perigo

Acute Tox. 3 Oral - Muta. 2 - Repr. 1B - STOT RE 1

Órgãos-alvo

Liver,Bone marrow

Código de classe de armazenamento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Lamentamos, não temos COA para este produto disponíveis online no momento.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 5

1 of 5

Methotrexate solution 1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

M-136

Methotrexate solution

vibrant-m

Y0000664

Methotrexate impurity E

Methotrexate

Sigma-Aldrich

454126

Methotrexate

vibrant-m

Y0000663

Methotrexate impurity C

Teriflunomide-D4 solution 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

Supelco

T-123

Teriflunomide-D4 solution

Joshua F Baker et al.
Annals of the rheumatic diseases, 73(11), 1968-1974 (2013-08-02)
To determine if early MRI measures predict X-ray progression at 1 and 2 years in a large RA trial cohort. This study included 256 methotrexate (MTX)-naïve RA patients from a randomised placebo-controlled trial of golimumab (GO-BEFORE). MRIs of wrist and 2nd-5th
Anna-Birgitte Aga et al.
Annals of the rheumatic diseases, 74(2), 381-388 (2013-11-29)
To investigate whether baseline disease activity levels and responses in patients with rheumatoid arthritis (RA) changed during the period 2000-2010. Data were provided by the Norwegian disease-modifying antirheumatic drug (NOR-DMARD) study. Patients with inflammatory joint diseases starting new treatment with
E Driehuis et al.
PloS one, 15(5), e0231588-e0231588 (2020-05-19)
We have recently established a protocol to grow wildtype human oral mucosa organoids. These three-dimensional structures can be maintained in culture long-term, do not require immortalization, and recapitulate the multilayered composition of the epithelial lining of the oral mucosa. Here
Axel Finckh et al.
Arthritis research & therapy, 16(5), 458-458 (2014-10-16)
Calcium pyrophosphate deposition (CPPD) may cause severe arthropathy, major joint destruction and treatment options are limited. The aim of this study was to test the therapeutic efficacy of methotrexate (MTX) in chronic or recurrent CPPD arthropathy. Patients with CPPD arthropathy
Giovanni L Mancardi et al.
Neurology, 84(10), 981-988 (2015-02-13)
To assess in multiple sclerosis (MS) the effect of intense immunosuppression followed by autologous hematopoietic stem cells transplantation (AHSCT) vs mitoxantrone (MTX) on disease activity measured by MRI. We conducted a multicenter, phase II, randomized trial including patients with secondary
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica